Education
About Us
Working with TipRanks
Follow Us
BioArctic AB Class B (DE:B9A)
FRANKFURT:B9A
B9A Stock Chart & Stats
€28.52
-€0.37(-2.00%)
At close: 4:00 PM EST
€28.52
-€0.37(-2.00%)
Day’s Range― - ―
52-Week Range€14.19 - €34.96
Previous CloseN/A
Volume0.00
Average Volume (3M)292.00
Market Cap
€2.55B
Enterprise Value€26.63B
Total Cash (Recent Filing)€2.19B
Total Debt (Recent Filing)€72.42M
Price to Earnings (P/E)26.9
Beta0.52
Next Earnings
May 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding74,241,486
10 Day Avg. Volume102
30 Day Avg. Volume292
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)13.99
Price to Sales (P/S)13.76
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€112.00M
Bulls Say, Bears Say
Bulls Say
2025 Profitability InflectionThe 2025 step-change to very high gross and net margins alongside accelerating revenue indicates the business can deliver meaningful economics when milestones/partnership payments occur. This structural uplift supports sustainable reinvestment, stronger ROE, and better partner leverage over the coming 2–6 months.
Conservative Balance SheetVery low leverage and an expanding equity base provide durable financial flexibility to fund R&D, support partnerships, and absorb setbacks without immediate refinancing. This conservative capital structure reduces insolvency risk and preserves optionality for licensing or co-development discussions.
Partnering/licensing Business ModelA focus on early-stage development plus partnering/licensing shifts late-stage and commercialization risk to larger pharma, while creating recurring milestone and royalty streams. This asset-light model can sustainably generate episodic high-margin cash inflows tied to partner execution and regulatory progress.
Bears Say
Volatile Profitability & Cash ConversionHistoric swings between large losses and sharp profit inflections suggest earnings are driven by timing of partner milestones rather than predictable operations. That volatility undermines confidence in recurring earnings and raises the risk that future profit swings could erode equity or force dilutive financing.
Revenue Concentration On Partner PaymentsHeavy reliance on a single partner and product for milestone and royalty income concentrates commercial and regulatory risk. Adverse outcomes or slower uptake at the partner level would materially reduce cash receipts and revenue visibility, limiting long-term stability of the business model.
Weak Free Cash Flow DurabilityOperating cash rebounded in 2025, but reported free cash flow of zero and prior negative FCF years show limited durability of internal cash generation. That uncertainty constrains reinvestment or increases dependency on partner funding or external capital during development cycles.
BioArctic AB Class B News
B9A FAQ
What was BioArctic AB Class B’s price range in the past 12 months?
BioArctic AB Class B lowest stock price was €14.19 and its highest was €34.96 in the past 12 months.
What is BioArctic AB Class B’s market cap?
BioArctic AB Class B’s market cap is €2.55B.
When is BioArctic AB Class B’s upcoming earnings report date?
BioArctic AB Class B’s upcoming earnings report date is May 20, 2026 which is in 57 days.
How were BioArctic AB Class B’s earnings last quarter?
BioArctic AB Class B released its earnings results on Feb 18, 2026. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.05 by €0.041.
Is BioArctic AB Class B overvalued?
According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued.
Does BioArctic AB Class B pay dividends?
BioArctic AB Class B does not currently pay dividends.
What is BioArctic AB Class B’s EPS estimate?
BioArctic AB Class B’s EPS estimate is -0.03.
How many shares outstanding does BioArctic AB Class B have?
BioArctic AB Class B has 74,241,486 shares outstanding.
What happened to BioArctic AB Class B’s price movement after its last earnings report?
BioArctic AB Class B reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.05. Following the earnings report the stock price went up 18.188%.
Which hedge fund is a major shareholder of BioArctic AB Class B?
Currently, no hedge funds are holding shares in DE:B9A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioArctic AB Class B
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---